Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.
The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
| Country | United States |
| Founded | 1986 |
| IPO Date | Oct 28, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Carl Spana |
Contact Details
Address: 11 Deer Park Drive, Suite 204 Monmouth Junction, New Jersey 08512 United States | |
| Phone | 609 495 2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | PTN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000911216 |
| CUSIP Number | 696077403 |
| ISIN Number | US6960776010 |
| Employer ID | 95-4078884 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Stephen T. Wills CPA, MST | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary |
| Burns McClellan | Vice President of Investor Relations |
| Stephen A. Slusher Esq. | Chief Legal Officer |
| James E. Hattersley B.A., M.S. | Senior Vice President of Business Development |
| John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | DEF 14A | Other definitive proxy statements |
| May 28, 2026 | CERT | Certification by an exchange approving securities for listing |
| May 28, 2026 | 8-A12B | Registration of securities |
| May 28, 2026 | 25 | Filing |
| May 18, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G | Filing |
| May 13, 2026 | 10-Q | Quarterly Report |
| Apr 23, 2026 | SCHEDULE 13G | Filing |